# A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab

> **NCT06042049** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 33 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** Nirsevimab

## Key facts

- **NCT ID:** NCT06042049
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-27
- **Primary completion:** 2025-07-24
- **Final completion:** 2025-07-24
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- IQVIA Pty Ltd

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06042049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06042049, "A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06042049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*